ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Although most people still view carbon dioxide (CO2) as a climate killer, industry is beginning to realise that CO2 could actually provide an abundant, low-cost feedstock for carbon-based processes. A number of Carbon Capture and Utilisation (CCU) schemes are evaluating the many different pathways that could play a role in the field in the future.
Europes first gene therapy company has floated on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimers expert Pharnext also went public.
The US has opened the floodgates to cheaper versions of biologic medicines, and analysts predict that by 2020, biosimilar protein meds could seize a significant share of a projected €390bn market. Thats good news for national health services and insurers, which stand to save billions in payouts. As expensive biologics begin to go off-patent, competitors with knockoffs are planning their onslaughts. But for biosimilars to have a future, both physicians and patients have to be sold on the idea – and many of them remain uninformed and unconvinced. The field is at a crucial juncture.
Designed to investigate the effects of strain or pressure to 2D and 3D cell cultures or the effects of fluid shear stress to 2D cultures, the Flexcell equipment offers its users various possibilities to set their cells under stress.
TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Sciences tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.
CarTheras ultrasound device opens a gate for therapeutic molecules into the brain, study shows.
With support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.
GATC Biotech, a leading provider of advanced genome analysis and diagnostic services, launched today INVIEW ONCOPANEL, a comprehensive multigene cancer panel for solid tumour profiling.
A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharmas recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.